Stoking protein production

How Stoke is attacking autosomal-dominant disorders with ASOs

Stoke Therapeutics Inc. is developing ASOs to boost normal protein expression as disease-modifying therapies for autosomal-dominant diseases that are not amenable to recombinant protein or gene therapies.

Co-founders Adrian Krainer and Isabel Aznarez previously discovered cell nuclei from patients with some autosomal-dominant disorders harbored reservoirs of precursor mRNA (pre-mRNA), transcribed from the wild-type allele of the disease-related gene, that did not undergo normal splicing.

Read the full 630 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE